Celularity Inc. Form 8-K Summary
Business Context and Reporting Period
Celularity Inc. filed a Form 8-K under Item 5.02 regarding changes to its board of directors and board committees. The report date was May 31, 2022, with related actions effective June 1–2, 2022. This filing does not report quarterly or annual financial results.
Financial Metrics and Liquidity
The filing does not provide revenue, profit or loss, cash flow, margins, debt, liquidity, or other operating or financial performance metrics.
Material Changes
- Jay R. Bloom, a Class I director and audit committee member, notified the board of his resignation effective June 1, 2022.
- The filing states that Mr. Bloom’s resignation was not due to any disagreement with Celularity regarding its operations, policies, or practices.
- John Sculley was appointed to the audit committee effective June 2, 2022.
- Diane Parks was appointed as a Class I director effective June 2, 2022, filling the vacancy created by Mr. Bloom’s resignation. She will serve until a successor is elected and qualified, or until earlier cessation of service.
Compensation, Outlook, and Risks
- Ms. Parks will receive compensation under Celularity’s standard non-employee director compensation practices.
- She received an option to purchase 42,413 shares of Class A common stock under the 2021 Equity Incentive Plan, with a stated grant-date value of $300,000 and an exercise price of $10.37 per share.
- The option has a 10-year term and vests in three equal annual installments, subject to continuous service and earlier termination provisions.
- Celularity entered into its standard indemnification agreement with Ms. Parks.
- The filing provides no financial guidance, business outlook, material contingencies, or unusual operating items.
Investor Verification Items
- Verify the effective dates of Mr. Bloom’s resignation, Mr. Sculley’s committee appointment, and Ms. Parks’ board appointment.
- Review the company’s current board and audit committee composition following these changes.
- Confirm the terms, vesting schedule, and share impact of Ms. Parks’ 42,413-share stock option.
- Consult Celularity’s other filings for financial performance, liquidity, capital needs, and business risks, which are not addressed in this Form 8-K.